DOCSLIB.ORG

Curtis Alexander Benson

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Curtis Alexander Benson Exploring Novel Therapies for Motor and Non-Motor Symptoms in a Mouse Model of Multiple Sclerosis. by Curtis Alexander Benson A thesis submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Centre for Neuroscience University of Alberta © Curtis Alexander Benson, 2016 Abstract Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by neurodegeneration, inflammation and demyelination. Symptoms of multiple sclerosis not only include motor deficits, but also secondary symptoms of pain, depression and anxiety. The purpose of this thesis was firstly to understand the underlying mechanism of these symptoms and secondly to investigate possible treatments. The first half of this thesis investigates the role of several key neurotransmitter systems in the progression and symptomatology of experimental autoimmune encephalomyelitis (EAE), an animal model for MS. The second half of this thesis examines whether exercise can modify the non-motor symptoms associated with EAE. Experiments in chapter 2 examined the effect of phenelzine (PLZ) in EAE. Daily PLZ treatment, starting seven days after disease induction, delayed EAE onset, reduced disease severity in the chronic phase and was associated with improvements in exploratory behaviour and a novel measure of sickness behaviour. EAE mice treated with daily PLZ showed a recovery in the levels of serotonin (5-HT) and norepinephrine (NE). In particular, EAE mice treated with PLZ showed a normalization of 5-HT levels in the ventral horn of the spinal cord. However, no differences were observed in the amount of T cell infiltration, microglia/macrophage reactivity, demyelination or axonal injury in PLZ-treated spinal cords. In chapter 3, we conducted experiments in which PLZ treatment only began when mice with EAE exhibited the first clinical signs of the disease, to determine whether PLZ could have beneficial effects in an already established disease state. Using this more clinically relevant treatment approach, we found that PLZ treatment reduced the severity of clinical signs and improved exploratory behaviours for the duration of the experiment in mice with EAE. These ii improvements were associated with higher levels of γ-aminobutyric acid (GABA), 5-HT, dopamine (DA) and NE in the brain and spinal cord. In chapter 4, work was undertaken to assess whether exercise could improve both the motor deficits and secondary symptoms of EAE. Allowing EAE mice 1 hour every day of voluntary running led to a significant delay in the onset of disease symptoms. The development of mechanical allodynia was assessed using Von Frey hairs and indicated that wheel running had a modest positive effect on the pain hypersensitivity associated with EAE. These behavioural changes were associated with decreased CNS inflammation, reduced oxidative stress and less mitochondrial protein expression. Unlike the case in chapters 2 and 3, voluntary wheel running led to only minor changes in neurotransmitter levels. The work done in chapter 5 further investigates the mitochondrial changes that occur during early EAE by examining the proteins involved in mitochondrial fission, fusion and biogenesis. EAE animals had increased levels of both the outer mitochondrial membrane protein Tom20 and the complex IV protein (COX IV) within the dorsal horn of the spinal cord compared to control mice. This increase was associated with an increase in the mitochondrial fission mediator, Drp1, a decrease in phosphorylated Drp1 at ser616, a decrease the fusion protein mitofusin 2 (MFN2), and a decrease in the expression of peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1α). The work in this thesis demonstrated the therapeutic potential of the monoamine oxidase (MAO) inhibitor PLZ and of daily exercise in MS. This study led to the identification of the role of several key neurotransmitters and also highlights mitochondrial dysfunction in the secondary symptoms of the disease. Further research into these mechanisms may lead to the development of novel therapies for MS. iii Preface This thesis is the original work of C. Benson. The projects and protocols used in this thesis have been approved by the University of Alberta animal care and use committee. Chapter 1 of thesis is an expanded version of the paper published by Benson C and Kerr BJ (2014) Pain and cognition in multiple sclerosis. Curr Top Behav Neurosci 20:201-15. C. Benson was involved in concept formation and manuscript composition and editing. B.J. Kerr was involved in manuscript editing and was the supervisory author. Chapter 2 of this thesis has been published as Musgrave T1, Benson C1, Wong G, Browne I, Tenorio G, Rauw G, Baker GB, Kerr BJ., (2011). The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE). Brain Behav Immun 25:1677-1688. T. Musgrave and C. Benson contributed equally to this work. T Musgrave was responsible for data collection and analysis of Figures 2.1 and 2.2 with assistance from C. Benson. C. Benson was responsible for data collection, analysis and preparation of figures 2.3-2.7 with assistance from G. Wong on figures 2.3 and 2.6. G. Rauw, G. Tenorio and I. Browne provided technical assistance. C. Benson, T. Musgrave and B.J. Kerr were involved in concept formation and manuscript composition and editing. G.B. Baker and B.J. Kerr were the supervisory authors. Chapter 3 of this thesis has been published as Benson C, Wong G, Tenorio G, Baker GB, Kerr BJ. (2013) The MAO inhibitor phenelzine can improve functional outcomes in mice with established clinical signs in experimental autoimmune encephalomyelitis (EAE). Behav Brain Res 252:302-311. C. Benson was responsible for data collection and analysis of figures 3.1, 3.5, 3.6 and 3.7. G. Wong, with direction and assistance from C. Benson, collected data for figures iv 3.2, 3.3 and 3.4. G. G. Tenorio provided technical assistance. C. Benson and B.J. Kerr were involved in concept formation and manuscript composition and editing. G.B. Baker and B.J. Kerr were the supervisory authors. Chapter 4 of this thesis has been published as Benson C1, Paylor JW1, Tenorio G, Winship I, Baker G, Kerr BJ. (2015). Voluntary wheel running delays disease onset and reduces pain hypersensitivity in early experimental autoimmune encephalomyelitis (EAE). Exp Neurol 271:279-290. C. Benson C and J.W. Paylor contributed equally to this project. C. Benson was responsible for data collection, analysis and preparation of figures 4.1, 4.2, 4.8 and 4.9. C. Benson performed immunohistochemistry and J.W. Paylor conducted image analysis and quantification for figures 4.3, 4.4, 4.5, 4.6, and 4.7. G. Tenorio provided technical assistance. I. Winship supervised the work of J.W. Paylor. C. Benson and B.J. Kerr were involved in concept formation and manuscript composition and editing. G.B. Baker and B.J. Kerr were the supervisory authors. Chapter 5 of this thesis is unpublished work. C. Benson was responsible for data collection and analysis for figures 5.1, 5.2, 5.3, 5.4, 5.5 and 5.6. S. Yousuf, M. Hubert and G. Tenorio provided technical assistance for figures 5.5 and 5.6. C. Benson and B.J. Kerr were involved in concept formation and manuscript composition and editing. B.J. Kerr were the supervisory authors. v “Every day is a new day. It is better to be lucky. But I would rather be exact. Then when luck comes you are ready.” ― Ernest Hemingway, The Old Man and the Sea vi Acknowledgements I would first like to thank my supervisor Dr. Bradley Kerr for all his support and allowing me to find my passion for scientific research. All the past and present members of the Kerr Lab deserve thanks for creating a supportive, collaborative and fun place to do my PhD. Especially, Camille, Travis, Liam, Katherine, Kevin and Saad. Thank you to everyone who provided me with technical advice and support. In particular, Gustavo Tenorio for keeping me sane by doing the Von Frey hair’s in many of my experiments and Gail Rauw for helping me to avoid Murphy’s Law when running the HPLC. Grace Wong and Wes Paylor deserve special credit for their diligent and impeccable cell staining and counting in chapters 3 and 4 of this thesis. I would like to thanks the department of Anesthesiology and Pain Medicine, the department of Pharmacology, Neuroscience and Mental Health Institute and the Multiple Sclerosis Society of Canada for their funding and support throughout my PhD work. I want to thank all my friends for their loyalty, motivation and the many games of darts. Thank you to my Mom, Dad and Haley for their unending support and for all the times they had to answer “what is Curtis doing again?” Finally, to Megan, thank you for listening, understanding and attempting to learn the areas of the brain. You push me to learn, explore and follow my dreams. I will always be grateful for your encouragement, kindness and love. vii Table of Contents CHAPTER 1 ................................................................................................................................... 1 General Introduction ....................................................................................................................... 1 1.1 MULTIPLE SCLEROSIS .................................................................................................... 2 1.2 BRIEF EPIDEMIOLOGY OF MS ...................................................................................... 2 1.2.1 MS Risk Factors.............................................................................................................
Load more

Recommended publications
  • Transport of Sugars
    BI84CH32-Frommer ARI 29 April 2015 12:34 Transport of Sugars Li-Qing Chen,1,∗ Lily S. Cheung,1,∗ Liang Feng,3 Widmar Tanner,2 and Wolf B. Frommer1 1Department of Plant Biology, Carnegie Institution for Science, Stanford, California 94305; email: [email protected] 2Zellbiologie und Pflanzenbiochemie, Universitat¨ Regensburg, 93040 Regensburg, Germany 3Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, California 94305 Annu. Rev. Biochem. 2015. 84:865–94 Keywords First published online as a Review in Advance on glucose, sucrose, carrier, GLUT, SGLT, SWEET March 5, 2015 The Annual Review of Biochemistry is online at Abstract biochem.annualreviews.org Soluble sugars serve five main purposes in multicellular organisms: as sources This article’s doi: of carbon skeletons, osmolytes, signals, and transient energy storage and as 10.1146/annurev-biochem-060614-033904 transport molecules. Most sugars are derived from photosynthetic organ- Copyright c 2015 by Annual Reviews. isms, particularly plants. In multicellular organisms, some cells specialize All rights reserved in providing sugars to other cells (e.g., intestinal and liver cells in animals, ∗ These authors contributed equally to this review. photosynthetic cells in plants), whereas others depend completely on an ex- Annu. Rev. Biochem. 2015.84:865-894. Downloaded from www.annualreviews.org ternal supply (e.g., brain cells, roots and seeds). This cellular exchange of Access provided by b-on: Universidade de Lisboa (UL) on 09/05/16. For personal use only. sugars requires transport proteins to mediate uptake or release from cells or subcellular compartments. Thus, not surprisingly, sugar transport is criti- cal for plants, animals, and humans.
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]
  • Glia Fiziológia Gliális Neurotranszmitter Transzporterek
    Glia fiziológia Gliális neurotranszmitter transzporterek Glutamát transzporterek asztrocitákban EAA- Excitatory Amino Acid Transporter (EAAT) család GLAST asztroglia, radiális glián (EAAT1) GLT1 (EAAT2) főleg asztroglia, de bizonyos neuronokon is EAAC1 (EAAT3) érett neuronok EAAT4 Purkinje sejtek, GABA-erg interneuronok, retina EAAT5 retina bipoláris és fotoreceptor sejtjei GLAST: Glutamate Aspartate Transporter GLT1: Glutamate Transporter 1 EAAC1: Excitatory Amino Acid Carrier 1 [Glu]EC: 2-5 uM (ez megnő persze neuron-tüzeléskor) [Glu]IC: 1-10 mM tehát Glu eltávolítás nagy koncentráció-gradienssel szemben kell, hogy történjen ! („uphill” translocation) Glia fiziológia Gliális neurotranszmitter transzporterek Glutamát transzporterek asztrocitákban be: 1 Glu-, 3 Na+, 1H+ glia ki: 1 K+ ionok koncentráció- gradiensük szerint mozognak alacsony Na+ic fenntartása kritikus a Glutamát elektrogén a transzporter mert uptake szempontjából !!! befelé irányuló áram van és deploarizáció: a benti + töltés tovább segíti a – glutamát felvételét Glia fiziológia Gliális neurotranszmitter transzporterek Glutamát transzporterek asztrocitákban Glutamát: sokféle ionmozgást okoz asztroban be: 1Glu- AMPAR aktiváció: 3Na+, 1H+ be: Na+ ki: K+ 1. Na+/K+ pumpa eredmény: net Na+ influx 2. Na+/Ca++ exchanger Na+ ~5mM 20-30 mM-ra nő ki: Na+ be: K+ ic (NCX) gyors megfordulása: energiaigényes és ki: Na+ be: Ca++ !!! lassabb ezt ellensúlyozza 1. és 2. Glia fiziológia Gliális neurotranszmitter transzporterek Glutamát transzporterek asztrocitákban alacsony Na+ic fenntartása
    [Show full text]
  • Frontiersin.Org 1 April 2015 | Volume 9 | Article 123 Saunders Et Al
    ORIGINAL RESEARCH published: 28 April 2015 doi: 10.3389/fnins.2015.00123 Influx mechanisms in the embryonic and adult rat choroid plexus: a transcriptome study Norman R. Saunders 1*, Katarzyna M. Dziegielewska 1, Kjeld Møllgård 2, Mark D. Habgood 1, Matthew J. Wakefield 3, Helen Lindsay 4, Nathalie Stratzielle 5, Jean-Francois Ghersi-Egea 5 and Shane A. Liddelow 1, 6 1 Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, VIC, Australia, 2 Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark, 3 Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia, 4 Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland, 5 Lyon Neuroscience Research Center, INSERM U1028, Centre National de la Recherche Scientifique UMR5292, Université Lyon 1, Lyon, France, 6 Department of Neurobiology, Stanford University, Stanford, CA, USA The transcriptome of embryonic and adult rat lateral ventricular choroid plexus, using a combination of RNA-Sequencing and microarray data, was analyzed by functional groups of influx transporters, particularly solute carrier (SLC) transporters. RNA-Seq Edited by: Joana A. Palha, was performed at embryonic day (E) 15 and adult with additional data obtained at University of Minho, Portugal intermediate ages from microarray analysis. The largest represented functional group Reviewed by: in the embryo was amino acid transporters (twelve) with expression levels 2–98 times Fernanda Marques, University of Minho, Portugal greater than in the adult. In contrast, in the adult only six amino acid transporters Hanspeter Herzel, were up-regulated compared to the embryo and at more modest enrichment levels Humboldt University, Germany (<5-fold enrichment above E15).
    [Show full text]
  • Human Glucose Transporters in Health and Diseases
    Human Glucose Transporters in Health and Diseases Human Glucose Transporters in Health and Diseases By Leszek Szablewski Human Glucose Transporters in Health and Diseases By Leszek Szablewski This book first published 2019 Cambridge Scholars Publishing Lady Stephenson Library, Newcastle upon Tyne, NE6 2PA, UK British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library Copyright © 2019 by Leszek Szablewski All rights for this book reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the copyright owner. ISBN (10): 1-5275-3558-4 ISBN (13): 978-1-5275-3558-9 CONTENTS Preface ...................................................................................................... vii Chapter 1 .................................................................................................... 1 Characteristics of Human Glucose Transporters Chapter 2 .................................................................................................... 5 Expression of Glucose Transporters in Health The human SLC2 (GLUT) family of membrane proteins ..................... 5 The human SLC5 (SGLT) family of membrane proteins .................... 30 The human SLC50 (SWEET) family of membrane proteins .............. 43 The role of glucose transporters in glucosensing machinery .............. 44 Chapter 3 .................................................................................................
    [Show full text]
  • General Aspects of Metal Ions As Signaling Agents in Health and Disease
    biomolecules Review General Aspects of Metal Ions as Signaling Agents in Health and Disease Karolina Krzywoszy ´nska 1,*, Danuta Witkowska 1,* , Jolanta Swi´ ˛atek-Kozłowska 1, Agnieszka Szebesczyk 1 and Henryk Kozłowski 1,2 1 Institute of Health Sciences, University of Opole, 68 Katowicka St., 45-060 Opole, Poland; [email protected] (J.S.-K.);´ [email protected] (A.S.); [email protected] (H.K.) 2 Faculty of Chemistry, University of Wrocław, 14 F. Joliot-Curie St., 50-383 Wrocław, Poland * Correspondence: [email protected] (K.K.); [email protected] (D.W.); Tel.: +48-77-44-23-549 (K.K); +48-77-44-23-548 (D.W.) Received: 25 August 2020; Accepted: 2 October 2020; Published: 7 October 2020 Abstract: This review focuses on the current knowledge on the involvement of metal ions in signaling processes within the cell, in both physiological and pathological conditions. The first section is devoted to the recent discoveries on magnesium and calcium-dependent signal transduction—the most recognized signaling agents among metals. The following sections then describe signaling pathways where zinc, copper, and iron play a key role. There are many systems in which changes in intra- and extra-cellular zinc and copper concentrations have been linked to important downstream events, especially in nervous signal transduction. Iron signaling is mostly related with its homeostasis. However, it is also involved in a recently discovered type of programmed cell death, ferroptosis. The important differences in metal ion signaling, and its disease-leading alterations, are also discussed.
    [Show full text]
  • Bioivt Transporter Catalog DG V3
    Transporter Assay Catalog Single Transporter Models Single Transporter Models Subcellular Transporter Relevance Gene Transporter Assay Species2 Cell Model3 Probe Substrate Inhibition 1 Localization in Type Type Assay Model Positive Control ASBT Bile acid uptake SLC10A2 Uptake IA H Apical MDCK-II Taurocholate NaCDC asc-1 Amino acid transport SLC7A10 Uptake IA H Basolateral MDCK-II Glycine Serine ASCT2 Amino acid transport SLC1A5 Uptake IA H Apical MDCK-II Glutamine Alanine ATB0+ Amino acid transport SLC6A14 Uptake IA H Apical MDCK-II Leucine N-Ethylmaleimide BAT1, CSNU3 Amino acid transport SLC7A9 Uptake IA H Apical MDCK-II Proline BCRP FDA & EMA DDI guidances; intestinal and BBB efflux, ABCG2 Efflux BD H Apical Caco-2 clone3 Genistein Chrysin biliary secretion, renal tubular secretion and drug resistance VA H, R N/A Vesicle CCK-8 Bromosulfophthalein BD H Apical MDCK-II Prazosin KO143 BSEP EMA DDI guidance; biliary secretion of bile salts, drug ABCB11 Efflux VA H, R, D N/A Vesicle Taurocholate Rifampicin induced liver injury CAT1 Amino acid transport SLC7A1 Uptake IA H Basolateral MDCK-II Arginine Lysine CAT2B Amino acid transport SLC7A2 Uptake IA H Basolateral MDCK-II Arginine CAT3 Amino acid transport SLC7A3 Uptake IA H Basolateral MDCK-II Arginine Lysine CHT Choline transport SLC5A7 Uptake IA H Basolateral MDCK-II Choline CNT1 Nucleoside uptake SLC28A1 Uptake IA H, R Apical MDCK-II Uridine Adenosine CNT2 Nucleoside uptake SLC28A2 Uptake IA H, R Apical MDCK-II Uridine Adenosine CNT3 Nucleoside uptake SLC28A3 Uptake IA H, R Apical MDCK-II
    [Show full text]
  • “The Transporter Transition”
    Inaugural Conference “The Transporter Transition” September 18 – September 21, 2018 University Clinic of Dentistry Vienna Sensengasse 2a, 1090 Vienna, Austria We gratefully acknowledge the support of the following sponsors: 2 Organizers: ITTS Executive Committee: President: Harald Sitte (Medical University of Vienna) Vice-President (USA): Lynette Daws (University of Texas Health Science Center at San Antonio) Vice-President (EU): Balazs Sarkadi (Hungarian Academy of Sciences) Secretary/Treasurer: Habibeh Khoshbouei (University of Florida) Past President: Haley E. Melikian (University of Massachusetts Medical School) Administrative Assistant ITTS/SFB35, Local support: Daniela Prinz (Medical University of Vienna) Registration: University of Vienna Event Management and Conference Services of the University of Vienna Universitätsring 1 1010 Vienna 3 Table of Contents Scientific Program ................................................................................................................................... 5 Plenary Lectures .................................................................................................................................... 16 Session 1 ................................................................................................................................................ 20 Session 2 ................................................................................................................................................ 24 Session 3 ...............................................................................................................................................
    [Show full text]
  • Antiepileptic Potential of Ganaxolone Antiepileptički Potencijal Ganaksolona
    Vojnosanit Pregl 2017; 74(5): 467–475. VOJNOSANITETSKI PREGLED Page 467 UDC: 615.03::616.853-085 GENERAL REVIEW https://doi.org/10.2298/VSP151221157J Antiepileptic potential of ganaxolone Antiepileptički potencijal ganaksolona Slobodan Janković, Snežana Lukić Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia Key words: Ključne reči: ganaxolone; epilepsies, partial; neurotransmitter ganaksolon; epilepsije, parcijalne; neurotransmiteri; agents; child; adult. deca; odrasle osobe. Introduction New anticonvulsants With its estimated prevalence of 0.52% in Europe, The drug resistant epilepsy has been recently defined by 0.68% in the United States of America and up to 1.5% in de- the International League Against Epilepsy as “a failure of veloping countries, epilepsy makes a heavy burden on indi- adequate trials of two tolerated, appropriately chosen and viduals, healthcare systems and societies in general all over used antiepileptic drug schedules (whether as monotherapies the world 1, 2. Despite long history of epilepsy treatment with or in combination) to achieve sustained seizure free- dom” 11.The mechanisms of drug resistance in epilepsy are medication, efficacy and effectiveness of available antiepi- still incompletely understood, and none of the anticonvul- leptic drugs as monotherapy were unequivocally proven in sants with current marketing authorization has demonstrated clinical trials only for partial-onset seizures in children and superior efficacy in the treatment of drug resistant epilepsy 12. adults (including elderly), while generalized-onset tonic- Using new anticonvulsants as add-on therapy lead to free- clonic seizures in children and adults, juvenile myoclonic dom from seizures in only 6% of patients with drug resistant epilepsy and benign epilepsy with centrotemporal spikes are epilepsy 13.
    [Show full text]
  • Glia Fiziológia I. Gliotranszmisszió
    Glia fiziológia I. Gliotranszmisszió Csatornák, receptorok Kapcsoltság, Ca++ Gliotranszmitterek Ioncsatornák Kapcsoltság Nem – vezikuláris release Aquaporinok Glia szincícium Vezikuláris release Neurotransz Gap junctions Transzporterek, egyéb mitter/neuro glia eredetű faktorok modulátor Hemichannels receptorok Gliális neurotranszmitter Asztro network transzporterek Glutamát receptorok térbeli/időbeli szabályozása Glutamát transzporterek GABA receptorok Gliális Ca++, GABA transzporterek Citokin és kemokin Ca++ hullámok receptorok Glycin transzporterek Endotelin Egyéb transzporterek receptorok Ozmolitikumok Komplement Glia eredetű neuropeptidek rendszer Glia eredetű Purinoreceptorok növekedési faktorok Glia fiziológia Gliális neurotranszmitter transzporterek Glutamát transzporterek asztrocitákban EAA- Excitatory Amino Acid Transporter (EAAT) család GLAST asztroglia, radiális glián (EAAT1) GLT1 (EAAT2) főleg asztroglia, de bizonyos neuronokon is EAAC1 (EAAT3) érett neuronok EAAT4 Purkinje sejtek, GABA-erg interneuronok, retina EAAT5 retina bipoláris és fotoreceptor sejtjei GLAST: Glutamate Aspartate Transporter GLT1: fő glu trporter az agyban GLT1: Glutamate Transporter 1 EAAC1: Excitatory Amino Acid Carrier 1 [Glu]EC: 1-5 uM (ez megnő persze neuron-tüzeléskor, akár több száz uM-ra (??)) [Glu]IC: 1-10 mM tehát Glu eltávolítás az ec. térből nagy koncentráció-gradienssel szemben kell, hogy történjen ! („uphill” translocation) GLUTAMÁT EXCITOTOXICITÁS GLUTAMÁT receptor overstimuláció Ca++ overload neuronpusztulás https://www.slideshare.net/shashikantbhargava/glutamate-seminar
    [Show full text]
  • Epigenetics of Aging and Alzheimer's Disease
    Review Epigenetics of Aging and Alzheimer’s Disease: Implications for Pharmacogenomics and Drug Response Ramón Cacabelos 1,2,* and Clara Torrellas 1,2 Received: 30 September 2015; Accepted: 8 December 2015; Published: 21 December 2015 Academic Editor: Sabrina Angelini 1 EuroEspes Biomedical Research Center, Institute of Medical Science and Genomic Medicine, 15165-Bergondo, Corunna, Spain; [email protected] 2 Chair of Genomic Medicine, Camilo José Cela University, 28692-Madrid, Spain * Correspondence: [email protected]; Tel.: +34-981-780505 Abstract: Epigenetic variability (DNA methylation/demethylation, histone modifications, microRNA regulation) is common in physiological and pathological conditions. Epigenetic alterations are present in different tissues along the aging process and in neurodegenerative disorders, such as Alzheimer’s disease (AD). Epigenetics affect life span and longevity. AD-related genes exhibit epigenetic changes, indicating that epigenetics might exert a pathogenic role in dementia. Epigenetic modifications are reversible and can potentially be targeted by pharmacological intervention. Epigenetic drugs may be useful for the treatment of major problems of health (e.g., cancer, cardiovascular disorders, brain disorders). The efficacy and safety of these and other medications depend upon the efficiency of the pharmacogenetic process in which different clusters of genes (pathogenic, mechanistic, metabolic, transporter, pleiotropic) are involved. Most of these genes are also under the influence of the epigenetic machinery. The information available on the pharmacoepigenomics of most drugs is very limited; however, growing evidence indicates that epigenetic changes are determinant in the pathogenesis of many medical conditions and in drug response and drug resistance. Consequently, pharmacoepigenetic studies should be incorporated in drug development and personalized treatments.
    [Show full text]
  • Zinc in the Retinal Pigment Epithelium and Choriocapillaris Interface
    Zinc in the Retinal Pigment Epithelium and Choriocapillaris Interface A Thesis Submitted to University College London for the degree of Doctor of Philosophy Sabrina Cahyadi BSc Department of Ocular Biology and Therapeutics Institute of Ophthalmology University College London 2012 1 Declaration I, Sabrina Cahyadi confirm that the work presented in the thesis titled “Zinc in the Retinal Pigment Epithelium and Choriocapillaris Interface” is my own work. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. ______________ Sabrina Cahyadi Date: 14 November 2011 2 Acknowledgements “For wisdom will enter your heart and knowledge will be pleasant to your soul; discretion will guard you, understanding will watch over you.” First and foremost, I would like to thank my supervisors Professor Phil Luthert and Dr. Imre Lengyel for accepting me as their student, and the enormous support, help and guidance they have provided. I would also like to thank the Dorothy Hodgkin Postgraduate Award, the Mercer Fund and Professor Alan Bird for their very generous studentship which enabled me to do this PhD. The funding I receive from the Special Trustees of Moorfields Eye Hospital allowed me to do my day-to-day lab works. I thank Peter Marshall who ensured that the funds reach me in time. I must also thank Dr. Peter Munro, Cynthia Langley, Alexandra Boss, and Dr. Virginia Calder for all the help and moral supports I have received. I cannot believe how much have happened in the past three years. The people at the Institute of Ophthalmology have supported me through all the amazing, good, bad, ho-hum, and heartbreaking episodes of my PhD.
    [Show full text]